Author:
Desai Devashish,Khan Adil Rashid,Soneja Manish,Mittal Ankit,Naik Shivdas,Kodan Parul,Mandal Ayan,Maher Ganesh Tarachand,Kumar Rohit,Agarwal Ayush,Gowda Naveen R,H Vikas,Kumar Parmeshwar,Pandey Shivam,Pandey R M,Kumar Arvind,Ray Animesh,Jorwal Pankaj,Nischal Neeraj,Choudhary Aashish,Brijwal Megha,Madan Karan,Lodha Rakesh,Sinha Sanjeev,Dar Lalit,Wig Naveet,Guleria Randeep
Reference11 articles.
1. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial;Ella;Lancet Infect Dis,2021
2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial;Ella;Lancet Infect Dis,2021
3. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial;Ella;Lancet,2021
4. Vaccine effects and impact of vaccination programmes in post-licensure studies;Hanquet;Vaccine,2013
5. Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 vaccines;Kahn;medRxiv,2021
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献